Market Overview:
The global mycosis fungoides treatment market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The market growth is attributed to the increasing incidence of mycosis fungoides, technological advancements in the field of mycosis fungoides treatment, and rising awareness about mycosis fungoides. However, the high cost associated with the treatment is expected to restrain the growth of this market during the forecast period. On the basis of type, HDAC inhibitors are projected to be one of fastest-growing segments in this market during forecast period owing their ability to improve patient outcomes and reduce side effects as compared with other treatments options available for MF patients.
Product Definition:
Mycosis fungoides (MF) is a rare form of cancer that begins in the skin's T-cells. MF usually starts as a rash on the skin that doesn't go away. The rash may be red, scaly, and itchy. Over time, it may become darker and thicker. MF can also affect other parts of the body, such as lymph nodes, internal organs, and blood vessels.
Mycosis fungoides treatment includes chemotherapy drugs called corticosteroids.
Topical Steroids:
Topical steroids are the drugs that are applied to the skin in order to reduce inflammation. They can be topically applied as creams, ointments, gels or liquids. Topical steroids can be used for various inflammatory conditions like acne, psoriasis and eczema.
Mechlorethamine Gel:
Mechlorethamine (MLT) is a medication used in the treatment of mycosis fungoides, a chronic skin disease characterized by raised levels of fungal elements such as yeast and fungus. MLT is applied topically to the affected areas on a daily basis for about 3-4 weeks. The gel form of mlt has proved to be more effective than cream or lotion forms in treating this condition.
Application Insights:
Based on the application, the global mycosis fungoides treatment market is segmented into hospitals, ambulatory surgical centers, and others. The hospital segment dominated the overall market in terms of revenue in 2017 owing to factors such as availability of advanced healthcare facilities along with highly skilled medical personnel. In addition, a large number of research studies have proved that systemic therapy is more effective than local treatment for MF patients thus influencing healthcare providers to opt for systemic over local therapy.
The others segment are characterized by less penetration compared to other segments and include clinics and extracorporeal photopheresis centers. These facilities are concentrated in developed countries only; therefore, their usage rates are relatively higher compared to developing countries due largely to lack of awareness about these treatments coupled with high cost associated with them which makes it inaccessible for most people especially those living below poverty line or without insurance coverage.
Regional Analysis:
North America dominated the global mycosis fungoides treatment market in 2017. The presence of favorable reimbursement policies, availability of highly skilled physicians and advanced healthcare infrastructure are some factors responsible for its large share. Moreover, increasing prevalence of cancer is also expected to drive regional growth over the forecast period. For instance, as per the American Cancer Society (ACS), Inc.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income coupled with growing awareness regarding early diagnosis & treatment options for various diseases including mycosis fungoides This can also be attributed towards improving healthcare facilities at a relatively lower cost as comparedto developed regions such as North America or Europe.
Growth Factors:
- Increasing incidence of mycosis fungoides
- Growing awareness about mycosis fungoides and its treatment options
- Rising demand for better and more effective therapies for mycosis fungoides
- Availability of novel treatments for mycosis fungoides
- Growing number of clinical trials for the treatment of mycosis fungoids
Scope Of The Report
Report Attributes
Report Details
Report Title
Mycosis Fungoides Treatment Market Research Report
By Type
Topical Steroids, Mechlorethamine Gel, HDAC Inhibitors, Monoclonal Antibodies, Localized Radiation Therapy, Extracorporeal Photopheresis, Others
By Application
Hospitals, Ambulatory Surgical Centers, Others
By Companies
Astellas Pharma, Bayer AG, Dover Medical and Scientific Equipment, Ltd., Elorac, Inc., Kyowa Kirin, Inc., Macopharma, Soligenix, Inc., Varian Medical Systems, Yaupon Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
141
Number of Tables & Figures
99
Customization Available
Yes, the report can be customized as per your need.
Global Mycosis Fungoides Treatment Market Report Segments:
The global Mycosis Fungoides Treatment market is segmented on the basis of:
Types
Topical Steroids, Mechlorethamine Gel, HDAC Inhibitors, Monoclonal Antibodies, Localized Radiation Therapy, Extracorporeal Photopheresis, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma
- Bayer AG
- Dover Medical and Scientific Equipment, Ltd.
- Elorac, Inc.
- Kyowa Kirin, Inc.
- Macopharma
- Soligenix, Inc.
- Varian Medical Systems
- Yaupon Therapeutics
Highlights of The Mycosis Fungoides Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Topical Steroids
- Mechlorethamine Gel
- HDAC Inhibitors
- Monoclonal Antibodies
- Localized Radiation Therapy
- Extracorporeal Photopheresis
- Others
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mycosis Fungoides Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Mycosis fungoides is a skin infection caused by the fungus Mycobacterium fungal. Treatment typically includes antibiotics and antifungal medications. In some cases, surgery may be necessary to remove the fungus from the skin.
Some of the major companies in the mycosis fungoides treatment market are Astellas Pharma, Bayer AG, Dover Medical and Scientific Equipment, Ltd., Elorac, Inc., Kyowa Kirin, Inc., Macopharma, Soligenix, Inc., Varian Medical Systems, Yaupon Therapeutics.
The mycosis fungoides treatment market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mycosis Fungoides Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Mycosis Fungoides Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Mycosis Fungoides Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Mycosis Fungoides Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Mycosis Fungoides Treatment Market Size & Forecast, 2018-2028
4.5.1 Mycosis Fungoides Treatment Market Size and Y-o-Y Growth
4.5.2 Mycosis Fungoides Treatment Market Absolute $ Opportunity
Chapter 5 Global Mycosis Fungoides Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Mycosis Fungoides Treatment Market Size Forecast by Type
5.2.1 Topical Steroids
5.2.2 Mechlorethamine Gel
5.2.3 HDAC Inhibitors
5.2.4 Monoclonal Antibodies
5.2.5 Localized Radiation Therapy
5.2.6 Extracorporeal Photopheresis
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Mycosis Fungoides Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Mycosis Fungoides Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Mycosis Fungoides Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Mycosis Fungoides Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Mycosis Fungoides Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Mycosis Fungoides Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Mycosis Fungoides Treatment Market Size Forecast by Type
9.6.1 Topical Steroids
9.6.2 Mechlorethamine Gel
9.6.3 HDAC Inhibitors
9.6.4 Monoclonal Antibodies
9.6.5 Localized Radiation Therapy
9.6.6 Extracorporeal Photopheresis
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Mycosis Fungoides Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Mycosis Fungoides Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Mycosis Fungoides Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Mycosis Fungoides Treatment Market Size Forecast by Type
10.6.1 Topical Steroids
10.6.2 Mechlorethamine Gel
10.6.3 HDAC Inhibitors
10.6.4 Monoclonal Antibodies
10.6.5 Localized Radiation Therapy
10.6.6 Extracorporeal Photopheresis
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Mycosis Fungoides Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Mycosis Fungoides Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Mycosis Fungoides Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Mycosis Fungoides Treatment Market Size Forecast by Type
11.6.1 Topical Steroids
11.6.2 Mechlorethamine Gel
11.6.3 HDAC Inhibitors
11.6.4 Monoclonal Antibodies
11.6.5 Localized Radiation Therapy
11.6.6 Extracorporeal Photopheresis
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Mycosis Fungoides Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Mycosis Fungoides Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Mycosis Fungoides Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Mycosis Fungoides Treatment Market Size Forecast by Type
12.6.1 Topical Steroids
12.6.2 Mechlorethamine Gel
12.6.3 HDAC Inhibitors
12.6.4 Monoclonal Antibodies
12.6.5 Localized Radiation Therapy
12.6.6 Extracorporeal Photopheresis
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Mycosis Fungoides Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Mycosis Fungoides Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Mycosis Fungoides Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Mycosis Fungoides Treatment Market Size Forecast by Type
13.6.1 Topical Steroids
13.6.2 Mechlorethamine Gel
13.6.3 HDAC Inhibitors
13.6.4 Monoclonal Antibodies
13.6.5 Localized Radiation Therapy
13.6.6 Extracorporeal Photopheresis
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Mycosis Fungoides Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Mycosis Fungoides Treatment Market: Competitive Dashboard
14.2 Global Mycosis Fungoides Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Astellas Pharma
14.3.2 Bayer AG
14.3.3 Dover Medical and Scientific Equipment, Ltd.
14.3.4 Elorac, Inc.
14.3.5 Kyowa Kirin, Inc.
14.3.6 Macopharma
14.3.7 Soligenix, Inc.
14.3.8 Varian Medical Systems
14.3.9 Yaupon Therapeutics
